Superficial Cervical Plexus Block for Pain Relief in Maxillofacial Surgery
This study aims to determine if a superficial cervical plexus block can delay the need for additional pain relief after maxillofacial surgery.
superficial cervical plexus nerve block
+ Bupivacaine
+ Saline (0.9% NaCl)
Treatment Study
Summary
Study start date: January 1, 2026
Actual date on which the first participant was enrolled.This study is focused on evaluating a pain relief method called the superficial cervical plexus block (SCPB) for people undergoing maxillofacial surgeries, which involve operations on the jaw and face. The researchers are comparing this method to the more common approach of general anesthesia. SCPB is a technique where a local anesthetic is injected near certain neck nerves to help reduce pain. The study is particularly important because it may offer a way to reduce the need for systemic painkillers that affect the whole body after surgery, potentially leading to fewer side effects and complications. Participants in the study will receive either the SCPB or general anesthesia before their surgery. The SCPB involves an injection guided by ultrasound to ensure accurate placement of the anesthetic. Researchers will measure several outcomes, including how long pain relief lasts, how much extra pain medication is needed after the surgery, pain levels using a visual analog scale, and any changes in vital signs. They'll also monitor for any complications that might arise from the procedure. Some potential risks of SCPB include injection into a blood vessel, hematoma (a collection of blood outside of blood vessels), infection, or local anesthetic toxicity, although these risks are generally lower than with deeper nerve blocks.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.70 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
Active ComparatorGroup II
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives